Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6252W HIGH $27.04
Volume
43.80 K
Value Traded
269.69 K
Short % Float
6.41%
Days to Cover
1.0
-17.67%Week
-42.92%1 Month
-63.19%3 Month
-83.03%6 Month
-99.99%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.67 M
EPS (TTM)
-6.73
P/E Ratio
-
Ent. Value
-1.76 M
Total Shares
2.58 M
Float Shares
3.64 M
Insiders
0.87%
Institutions
0.82%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CLDI Catalyst Timeline
Dated clinical, regulatory and corporate events for Calidi Biotherapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Calidi Biotherapeutics, Inc.
220Total events
17Upcoming
19Tier-1 (high impact)
2022 to 2028Coverage
Upcoming catalysts 2
Event history 50
▼Other Regulator MilestoneEx-US Regulatory
NYSE American notice of non-compliance with stockholders' equity continued listing standard
▼Equity OfferingCorporate
Registered direct offering of 1,025,640 shares at $1.17 per share for ~$1.2 million gross proceeds
●Oral PresentationPresentation
Virtual presentation available on-demand for H.C. Wainwright conference
●Oral PresentationCLD-401Presentation
Presented new data on CLD-401 at AACR D3 Conference
metastatic non-small cell lung cancer, head and neck cancer, and other tumor typessource ↗
◆Oral PresentationPresentation
New data on cytotoxicity and IL-15 SA expression in murine tumor cells at AACR D3
solid tumorssource ↗
◆Poster PresentationCLD-501Presentation
Poster presentation of CLD-501 data at T-cell Engager Therapeutic Summit
solid tumors (TROP2-positive)source ↗
▲FDA Feedback ReceivedCLD-401FDA Meeting
Received positive pre-IND feedback from FDA for CLD-401
non-small cell lung cancer, head and neck cancer, and other tumor typessource ↗
▲FDA Feedback ReceivedCLD-401FDA Meeting
Positive pre-IND feedback from FDA for CLD-401
metastatic non-small cell lung cancer, head and neck cancer, and other tumor typessource ↗
●Oral PresentationCLD-501Presentation
Presented preclinical data on CLD-501 at 2026 ASCO Annual Meeting
●Oral PresentationCLD-401Presentation
Presented preclinical data on CLD-401 at 2026 ASCO Annual Meeting
◆Preclinical PoCCLD-401Preclinical
Preclinical data on CLD-401 to be presented at ASCO 2026
non-small cell lung cancer, head and neck cancer, and other tumor typessource ↗
◆Preclinical PoCCLD-501Preclinical
Preclinical data on CLD-501 to be presented at ASCO 2026
solid tumorssource ↗
●AbstractPresentation
Two abstracts on RedTail platform accepted for online publication at 2026 ASCO Annual Meeting
●IND Enabling CompleteCLD-401Preclinical
CLD-401 currently in IND-enabling studies
non-small cell lung cancer, head and neck cancer, and other tumor typessource ↗
◆Oral PresentationPresentation
Speaker presentation at ASGCT conference highlighting RedTail platform data
◆Oral PresentationCLD-401Presentation
Speaker presentation at ASGCT 2026 on CLD-401 IL15-SA expression
non-small cell lung cancer, head and neck cancer, and other tumor typessource ↗
▲Partnership / LicenseCorporate
Strategic partnership with TransferAI for CLD-401 IND submission using AI
◆Poster PresentationCLD-401Presentation
New data on CLD-401 presented at AACR annual meeting
non-small cell lung cancer, head and neck cancer, and other tumor typessource ↗
●Poster PresentationPresentation
Data presented on RedTail platform and CLD-401 at AACR 2026
solid tumorssource ↗
◆Oral PresentationCLD-501Presentation
Presented data on RedTail platform and CLD-501 at AACR 2026
solid tumorssource ↗
◆Oral PresentationPresentation
Presentation of new data on RedTail platform with T-cell engagers at AACR 2026
solid tumorssource ↗
▲Partnership / LicenseCLD-401Corporate
Strategic partnership with TransferAI for CLD-401 IND submission
●IND SubmissionCLD-401IND
IND submission for CLD-401
non-small cell lung cancer, ovarian cancer, and other tumor typessource ↗
●IND Enabling CompleteCLD-401Preclinical
Completion of IND-enabling studies for CLD-401
non-small cell lung cancer, ovarian cancer, and other tumor typessource ↗
●IND SubmissionRedTailIND
IND filing expected for Redtail lead candidate
non-small cell lung cancer, ovarian cancer, and other tumor typessource ↗
●IND Enabling CompleteCLD-401Preclinical
CLD-401 currently in IND-enabling studies
non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical needsource ↗
▲Partnership / LicenseCLD-401Corporate
Partnership with Avance Clinical to accelerate initiation of CLD-401 clinical trial in Australia
▲FDA Feedback ReceivedCLD-401FDA Meeting
FDA Type D meeting feedback received supporting manufacturing and analytical approaches for CLD-401
●Oral PresentationPresentation
Presented data on in situ T-cell engagers (TCEs) at AACR-IO conference
solid tumorssource ↗
▲Partnership / LicenseCorporate
Partnership with Avance Clinical to facilitate Australian regulatory approval and accelerate CLD-401 trial initiation
●Oral PresentationCLD-401Presentation
Presentation on CLD-401 manufacturing process at BioProcessing Summit
non-small cell lung cancer, head and neck cancer, and other tumor typessource ↗
●Type D MeetingCLD-401FDA Meeting
FDA Type D meeting request process for CLD-401 manufacturing
▲FDA Feedback ReceivedCLD-401FDA Meeting
FDA feedback supporting CLD-401 manufacturing process
▼Equity OfferingCorporate
Closing of $6.0 million underwritten public offering and full exercise of over-allotment option
◆Equity OfferingCorporate
Calidi announces proposed public offering of units consisting of common stock, pre-funded warrants, and common warrants
Past FDA Catalysts and PDUFA Decisions
How CLDI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-24 | CLD-401 | Pre-clinical data presentation | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every CLDI program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Camaisa AllanDirector | Sell | -850 76,952 held | $1.46 | 12/12/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in CLDI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CLDI for Q2 2026. | ||||
CLDI Institutional Ownership Trends
CLDI Short Interest
Shares sold short, counted twice a month.
6.41%
Short % of Float
of tradable shares sold short
233.3K
Shares Sold Short
+2.4% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
380.1K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CLDI ranks across every disease it competes in
Competitive Position is a premium feature
See how CLDI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCLDI News
CLDI▼ -6.4%on this news· ran to -22% by day 3
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
Calidi Biotherapeutics will present new data on its CLD-401 program and advances in its In Situ TCE platform at the ESMO Congress 2026. The presentations will highlight the effectiveness of CLD-401 in targeting tumors and its ability to drive immune responses. Additionally, data on the company's T-cell engager candidates will showcase their potential in enhancing localized tumor treatment. This marks a significant step in the development of their RedTail platform.
Read more →CLDI▼ -5.3%on this news
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
Calidi Biotherapeutics has received a notification from NYSE American regarding its non-compliance with listing standards due to insufficient stockholders' equity. The company is required to submit a compliance plan by October 21, 2026, to avoid potential delisting. Despite this, trading of its stock will continue, though marked as below compliance.
Read more →CLDI▲ +8.5%on this news
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
Calidi Biotherapeutics announced a registered direct offering of 1,025,640 shares at $1.17 per share, expected to raise approximately $1.2 million. The proceeds will be used for working capital and corporate purposes. The offering is part of a shelf registration statement effective since October 2024. Calidi is advancing its RedTail platform targeting metastatic cancers.
Read more →CLDICalidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Calidi Biotherapeutics will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. CEO Eric Poma will engage in one-on-one investor meetings, and a virtual presentation will be available on-demand starting September 11. The company is advancing its pipeline, focusing on targeted therapies for metastatic cancers using its proprietary RedTail platform.
Read more →CLDICalidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Calidi Biotherapeutics reported its financial results for Q2 2026, highlighting positive FDA feedback for its CLD-401 drug candidate and showcasing new data from its RedTail platform at the ASCO Annual Meeting. The company significantly reduced administrative expenses and strengthened its board with a new member. Despite a net loss, Calidi remains focused on advancing its clinical pipeline.
Read more →CLDI▲ +9.5%on this news
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
Calidi Biotherapeutics presented new data at the AACR D3 Conference, highlighting advancements in its CLD-401 program and in situ T-cell engager development. The company aims to begin clinical trials for CLD-401 in early 2027, showcasing the potential of its RedTail platform in delivering genetic medicines to metastatic tumors. However, risks related to funding and regulatory approval remain.
Read more →CLDI▼ -13.9%on this news
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
Calidi Biotherapeutics provided a mid-year update highlighting positive pre-IND feedback from the FDA for its lead candidate CLD-401, which is set to enter a first-in-human study in Q1 2027. The company showcased advancements in its RedTail platform, including new data on in situ T-cell engagers. Additionally, Calidi has reduced its general and administrative costs significantly and strengthened its Board with experienced executives.
Read more →CLDI▼ -13.9%on this newsshared move
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Calidi Biotherapeutics announced a 1-for-16 reverse stock split, effective July 31, 2026. This decision aims to enhance market dynamics and attract more investors. Stockholders will see their shares consolidated, with adjustments made for fractional shares. The company continues to develop its RedTail platform for targeted genetic therapies.
Read more →CLDI▲ +5.3%on this news
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
Calidi Biotherapeutics announced the approval of a stock option grant for Sandra Gurrola, newly appointed VP Finance. The grant includes 100,000 shares at an exercise price of $0.15, vesting over four years. This move aligns with Calidi's strategy to enhance its leadership team as it advances its RedTail platform for targeted cancer therapies.
Read more →CLDICalidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
Calidi Biotherapeutics presented new data on its T-cell engager candidate CLD-501 at the T-cell Engager Therapeutic Summit. The data highlights the efficacy of the RedTail platform in activating T-cells and expressing T-cell engagers directly in the tumor microenvironment. This approach aims to address challenges faced by T-cell engagers in solid tumors, particularly with TROP2 targeting.
Read more →CLDICalidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
Calidi Biotherapeutics has appointed Dr. Corsee Sanders to its Board of Directors, effective June 17, 2026. Dr. Sanders brings a wealth of experience from her previous roles at Genentech/Roche and Celgene. Her expertise in the clinical development of novel therapeutics is anticipated to significantly benefit Calidi as it advances its lead candidate, CLD-401, and the RedTail platform.
Read more →CLDICalidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
Calidi Biotherapeutics has received favorable pre-IND feedback from the FDA regarding its development strategy for CLD-401, a targeted oncolytic virus therapy. This feedback aligns with the company's plans to initiate a first-in-human clinical trial in early 2027. The FDA's agreement on key aspects of the clinical study design supports Calidi's IND-enabling efforts.
Read more →CLDICalidi Biotherapeutics Announces Investor Webinar on June 9, 2026
Calidi Biotherapeutics will host an investor webinar on June 9, 2026, featuring CEO Eric Poma. The event will cover the RedTail platform's advancements, including the lead candidate CLD-401, which targets various cancers. The discussion will also highlight upcoming milestones and the platform's broader potential. A live Q&A will follow the presentation.
Read more →CLDICalidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
Calidi Biotherapeutics announced the acceptance of two abstracts for the 2026 ASCO Annual Meeting, showcasing their RedTail platform's capabilities. The company will present preclinical data on its lead programs, CLD-401 and CLD-501, which aim to enhance immune responses against tumors. Calidi plans to file an IND for CLD-401 by the end of 2026, while continuing to seek strategic partnerships.
Read more →CLDI▼ -8.4%on this newsshared move
Calidi Biotherapeutics Provides Required NYSE American Disclosure
Calidi Biotherapeutics disclosed that its Financial Statements for 2025 included an audit report highlighting the assumption of continuing as a going concern. This disclosure is mandated by NYSE regulations and does not alter previous filings. The company is advancing its RedTail platform, targeting various cancers with its lead candidate, CLD-401.
Read more →CLDI▼ -5%on this news
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics reported its Q1 2026 financial results, highlighting advancements in its CLD-401 and RedTail platform. The company presented new data at the AACR conference, showcasing immune changes induced by CLD-401 and the innovative use of T-cell engagers. A strategic partnership with TransferAI aims to enhance the IND submission process, while the company recorded a significant reduction in administrative expenses.
Read more →CLDI▲ +8.1%on this newsshared move
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston
Calidi Biotherapeutics will feature Dr. Antonio F. Santidrian at the ASGCT Conference in Boston, discussing the promising RedTail platform and its lead candidate CLD-401. This virotherapy aims to selectively target tumors and enhance immune response. The company plans to file an IND for CLD-401 by the end of 2026.
Read more →CLDI▼ -6.9%on this news
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
Calidi Biotherapeutics has announced a strategic partnership with TransferAI to enhance the IND submission process for its lead candidate, CLD-401, utilizing TransferAI's artificial intelligence platform, Sofie. This collaboration aims to streamline regulatory workflows and support Calidi's objective of submitting its IND by the end of the year. CLD-401, part of the RedTail platform, is designed to target tumors effectively by utilizing an engineered oncolytic virus. The partnership is expected to bolster Calidi's regulatory efforts as it advances towards clinical trials for this promising therapeutic candidate.
Read more →CLDI▼ -11.4%on this news
Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
Calidi Biotherapeutics presented new data on its lead asset, CLD-401, at the AACR Annual Meeting in San Diego on April 21, 2026. CLD-401 is an oncolytic virus designed to express high levels of IL-15 superagonist within the tumor microenvironment and has shown promising results in preclinical models. The company plans to file an IND application by the end of 2026, aiming to enter clinical trials soon after. This data highlights the potential of Calidi's RedTail platform to enhance immune response against various cancers.
Read more →CLDI▼ -9%on this news· ran to -20% by day 3shared move
Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
Calidi Biotherapeutics presented new data at the AACR annual meeting highlighting its RedTail platform's ability to activate T-cells while delivering T-cell engagers directly in the tumor microenvironment. The company is also developing CLD-501, a candidate specifically targeting TROP-2, a challenge due to potential off-target toxicity. The platform aims to overcome historical limitations seen in solid tumors by remodeling the tumor environment for better T-cell efficacy. Calidi aims to expedite the clinical development of its therapies while pursuing additional targets.
Read more →About Calidi Biotherapeutics, Inc.
Headquarters4475 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next CLDI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime